In brief, hair loss associated with GLP1 receptor agonist medications, semaglutide, osempic wagovy, pterzipatide, munjaro, zeppound, and other agents in this class has moved from anecdotal social media reports to peer-reviewed systematic review, site index equals sign 19 to 1 inches. More than 1,000 spontaneous cases have been reported in the U.S. alone. A 2025 meta-analysis of more than 84,000 participants found GLP1 users were approximately 3.4 times more likely to experience hair loss than non-users. Two 2026 systematic reviews confirmed the signal. The mechanism is primarily rapid weight loss-driven telogenifluvium, not direct drug toxicity to the follicle. The alopecia is predominantly non-scarring, follicles remain intact, and regrowth is biologically possible. Here is the complete evidence-based picture. What the 2026 evidence actually shows, three key publications establish the current evidence base. The 2026 Gupta Systematic Review, the most comprehensive, site index equals sign, 17 to 1 inches. Of 133 studies identified, 24 met inclusion criteria. Among GLP1RAs, semaglutide and tirzepatide demonstrated the highest incidence rates of hair loss, and more frequent signal detection in pharmacovigilance studies. Although infrequently classified overall, androgenetic alopecia and telogen effluvium were the predominant subtypes of hair loss reported. Tearzepatide associated with the greatest magnitude of weight loss was most frequently linked to telogen efluvium. Hair loss associated with semagluti. D appeared to be dose-dependent, with doses 2 mg weekly rarely implicated, while higher obesity treatment doses were more common. The dose dependency finding is clinically significant. Semaglutide at diabetes treatment doses, 0.5-1 mg weekly, is rarely implicated in hair loss. The higher obesity treatment doses, up to 2.4 mg weekly for Wegovi, produce the weight loss magnitude that drives the TE mechanism. The Bronitsky Systematic Review, IJD, October 2025, cite index equal sign 18 to 1 inches. Pharmacovigilance and modeling analyses examined a total of 920,890 adverse events. GLP1 RAs investigated included semaglutide and terzipatide with the strongest pharmacovigilance signals. Multiple pharmacovigilance analysis studies identified a weak association between GLP1RA use and hair loss, most commonly with semaglutide, reporting odds ratio 1.24-2.46, followed by tersipatide, ROR0.83-1.73. The reporting odds ratio for semaglutide above 1.0 indicates more hair loss reports than expected for a drug of this usage frequency. A pharmacovigilance signal, not a causal confirmation, but one that is consistent across multiple databases. The Trinity X Multicenter Cohort, real-world data, site index equal sign, 21 to 1 inches, the Trinit X multicenter cohort study compared GLP1RA users against matched controls across multiple health systems. At six months on therapy, increased risk of androgenetic alopecia, AOR 1.62, and non-scarring hair loss, AOR 1.26. At 12 months on therapy, telogen effluvium, AOR 1.76, androgen, tick alopecia, AOR 1.64, and non-scarring hair loss, AOR 1.40. The adjusted odds ratios above 1.0 confirm that the signal holds after controlling for other variables. The AGA finding at 12 months, AOR 1.64, is the more surprising result, suggesting GLP1 medications may be unmasking or accelerating underlying AGA in predisposed individuals, not only producing T3. Forpex higher hair loss risk for GLP1 users versus non-users. 2025 meta-analysis of 84,000 plus participants. The largest dataset yet on this association. AOR 1.76 adjusted odds ratio for telegenafluvium at 12 months. TRINETX Multicenter Cohort 2026. Real-world multi-health system data matching GLP1 users to controls. Dose-dependent semaglutide below 2 mg weak, rarely implicated. Higher obesity treatment doses, WIGO V2.4 mg weak, produce the weight loss magnitude that drives TE. Titration pace matters. What is the mechanism? Is it the drug or the weight loss? Site index equal sign, 20 to 1 inches. The primary mechanism is telogen effluvium. This is not direct drug toxicity to the follicles. The medication is not damaging hair roots. Instead, GLP1-induced appetite suppression leads to significant caloric restriction, which produces rapid weight loss. The body registers this as physiological stress, follicles synchronize into the resting phase, and shedding appears too, four months later. The Crash Diet and Hair Loss article, August 21st, covered this mechanism in detail. Severe caloric restriction triggers TE through protein deficiency and the physiological stress signal that pushes follicles into telogen. GLP1-induced TE is the same mechanism operating at greater speed and magnitude than most voluntary caloric restriction, because the appetite suppression from these medications can produce 15 to 20% body weight loss within a year. Three additional mechanisms are proposed alongside the primary TE pathway. Nutritional deficiencies from reduced intake. The satiety effect of GLP1 medications reduces food volume substantially, potentially producing protein, iron, zinc, and vitamin D insufficiency that compounds the caloric restriction TE. This is the most modifiable concurrent risk factor. AGA unmasking, the TrinideX AOR 1.64 for AGA at 12 months suggests GLP1 medications may unmask or accelerate underlying androgenetic alopecia, possibly through insulin IGF-1 pathway changes, stress-related androgen changes, or nutritional deficiencies that amplify existing AGA. This mirrors the FPHL unmasking mechanism from the post-pill article. Direct GLP1 receptor effects at the follicle, site index equal sign, 18 to 1 inches, hormonal changes, particularly involving insulin and insulin-like growth factor, rapid weight loss, and the psychosocial stress of managing chronic disease may influence androgen production or the hair follicle cycle. GLP1 receptors are expressed in multiple tissues beyond the gut. Whether they are expressed in scalp follicles and have direct effects is under investigation, but not yet confirmed. Tirzipatide versus semagluti